| Literature DB >> 28695359 |
Annemarie M den Harder1, Martin J Willemink2, Pieter J van Doormaal3, Frank J Wessels2, M T W T Lock4, Arnold M R Schilham2, Ricardo P J Budde3, Tim Leiner2, Pim A de Jong2.
Abstract
OBJECTIVE: To assess the performance of hybrid (HIR) and model-based iterative reconstruction (MIR) in patients with urolithiasis at reduced-dose computed tomography (CT).Entities:
Keywords: Diagnostic; Imaging; Multidetector computed tomography; Radiation ionising; Sensitivity; Urolithiasis
Mesh:
Year: 2017 PMID: 28695359 PMCID: PMC5717126 DOI: 10.1007/s00330-017-4929-2
Source DB: PubMed Journal: Eur Radiol ISSN: 0938-7994 Impact factor: 5.315
Stone and calcification characteristics
| Diameter | Total | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| <3 mm | 3–5 mm | 5–10 mm | >10 mm | ||||||
| n | Density (HU) | n | Density (HU) | n | Density (HU) | n | Density (HU) | ||
| Stone | 16 | 307 (251–371) | 23 | 365 (323–531) | 16 | 720 (541–897) | 8 | 822 (665–982) | 63 |
| Papillary calcification | 2 | 333 (257–333) | 1 | 335 | 4 | 837 (645–1237) | 0 | NA | 7 |
| Parenchymal calcification | 1 | 481 | 2 | 312 (258–312) | 1 | 694 | 0 | NA | 4 |
| Total | 19 | 26 | 21 | 8 | 74 | ||||
Diagnostic performance. The sensitivity for stone detection was calculated on a patient level, and stones, papillary calcifications and parenchymal calcifications were combined. Two patients did not have any stones. The sensitivity is presented as median (interquartile). For the assessment of extra-urinary tract pathology the number [percentage] of non-assessable reconstructions is displayed per observer
| Sensitivity | Cholecys-tectomy | Gall bladder stones | Gall bladder wall thickening | Sigmoid diverticulitis | Appendix visible | Appendicitis | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Routine dose | Obs. 1 | Obs. 2 | Obs. 1 | Obs. 2 | Obs. 1 | Obs. 2 | Obs. 1 | Obs. 2 | Obs. 1 | Obs. 2 | Obs. 1 | Obs. 2 | |
| FBP | 94.4 (80.0–100.0) | 0 [0] | 0 [0] | 1 [5] | 1 [5] | 1 [5] | 8 [42] | 0 [0] | 0 [0] | 0 [0] | 1 [5] | 0 [0] | 2 [11] |
| HIR | 100.0 (80.0–100.0) | 0 [0] | 0 [0] | 1 [5] | 1 [5] | 2 [11] | 2 [11] | 0 [0] | 0 [0] | 0 [0] | 1 [5] | 0 [0] | 1 [5] |
| MIR (BR) | 100.0 (92.9–100.0) | 0 [0] | 0 [0] | 0 [0] | 1 [5] | 0 [0] | 3 [16] | 0 [0] | 0 [0] | 1 [5] | 1 [5] | 1 [5] | 1 [5] |
| MIR (ST) | 100.0 (77.8–100.0) | 0 [0] | 0 [0] | 1 [5] | 1 [5] | 1 [5] | 2 [11] | 0 [0] | 0 [0] | 2 [11] | 1 [5] | 1 [5] | 2 [11] |
| 40% reduced dose | |||||||||||||
| FBP | 88.9 (50.0–100.0) | 0 [0] | 0 [0] | 1 [5] | 2 [11] | 4 [21] | 16 [84] | 0 [0] | 0 [0] | 0 [0] | 2 [11] | 0 [0] | 3 [16] |
| HIR | 100.0 (80.0–100.0) | 0 [0] | 0 [0] | 1 [5] | 1 [5] | 4 [21] | 8 [42] | 0 [0] | 0 [0] | 1 [5] | 1 [5] | 1 [5] | 2 [11] |
| MIR (BR) | 100.0 (92.9–100.0) | 0 [0] | 0 [0] | 1 [5] | 1 [5] | 1 [5] | 4 [21] | 0 [0] | 0 [0] | 0 [0] | 1 [5] | 0 [0] | 2 [11] |
| MIR (ST) | 100.0 (92.9–100.0) | 0 [0] | 0 [0] | 1 [5] | 1 [5] | 1 [5] | 5 [26] | 0 [0] | 0 [0] | 1 [5] | 0 [0] | 2 [5] | 2 [11] |
| 60% reduced dose | |||||||||||||
| FBP | 87.5 (50.0–100.0) | 0 [0] | 0 [0] | 2 [11] | 5 [26] | 7 [37] | 19 [100] | 0 [0] | 0 [0] | 2 [11] | 4 [21] | 4 [21] | 5 [26] |
| HIR | 88.9 (75.0–100.0) | 0 [0] | 0 [0] | 1 [5] | 2 [11] | 5 [26] | 13 [68] | 0 [0] | 0 [0] | 1 [5] | 1 [5] | 0 [0] | 5 [26] |
| MIR (BR) | 100.0 (81.3–100.0) | 0 [0] | 0 [0] | 1 [5] | 1 [5] | 2 [11] | 8 [42] | 0 [0] | 0 [0] | 0 [0] | 1 [5] | 0 [0] | 1 [5] |
| MIR (ST) | 100.0 (80.0–100.0) | 0 [0] | 0 [0] | 1 [5] | 1 [5] | 3 [16] | 4 [21] | 1 [5] | 0 [0] | 1 [5] | 1 [5] | 1 [5] | 1 [5] |
| 80% reduced dose | |||||||||||||
| FBP | 50.0 (16.7–100.0) | 1 [5] | 3 [15] | 14 [74] | 14 [74] | 18 [95] | 10 [100] | 17 [90] | 8 [42] | 16 [84] | 16 [84] | 18 [95] | 16 [84] |
| HIR | 72.2 (62.5–100.0) | 0 [0] | 0 [0] | 4 [21] | 6 [32] | 11 [58] | 18 [95] | 1 [5] | 0 [0] | 6 [32] | 3 [16] | 4 [21] | 6 [32] |
| MIR (BR) | 100.0 (68.8–100.0) | 0 [0] | 0 [0] | 2 [11] | 3 [16] | 4 [21] | 9 [47] | 1 [5] | 0 [0] | 1 [5] | 1 [5] | 1 [5] | 4 [21] |
| MIR (ST) | 78.6 (50.0–100.0) | 0 [0] | 0 [0] | 1 [5] | 1 [5] | 4 [21] | 11 [58] | 0 [0] | 0 [0] | 0 [0] | 2 [11] | 2 [11] | 2 [11] |
FBP filtered back projection, HIR hybrid iterative reconstruction, MIR model-based iterative reconstruction, BR body routine, ST soft tissue, Obs observer
Fig. 1Example of decreased sensitivity for stone detection. From left to right the stone at routine dose reconstructed with FBP (a), the FBP reconstruction at the lowest dose level on which the stone was missed (b) and the IR reconstructions (HIR, MIR Body Routine and MIR Soft Tissue) at the same dose level on which the stone is clearly visible
Fig. 2Example of the subjective image quality score. From left to right the different scores: score 1 with FBP at 80% reduced dose, score 2 with HIR at 80% reduced dose, score 3 with MIR Soft Tissue at 60% reduced dose and score 4 with HIR at the routine dose level. Note that the kidney stone can be seen in all images. Score 1 was mainly because of excessive noise. Score 2 was also due to substantial noise. Score 3 was given because of smoothening by IR. Score 4 contains some noise, but radiologists are used to some noise and tend to prefer this to extensive smoothening and noise reduction
Subjective image quality and noise per reconstruction method and per dose level. For the image quality, the average score of the two observers was used. Those data are presented as median [interquartiles]. Also, the number of examinations [%] with unacceptable image quality (score 1 or 2) is shown per observer. The noise is presented as medians (interquartiles)
| Subjective image quality | Unacceptable image quality | Renal cortex (right) | Renal cortex (left) | Aorta | Retroperitoneal fat | Air | ||
|---|---|---|---|---|---|---|---|---|
| Routine dose | Obs. 1 | Obs. 2 | ||||||
| FBP | 3 [3–3] | 0 [0] | 9 [47] | 53.3 (48.6–61.2) | 51.8 (42.8–60.0) | 56.5 (50.3–68.8) | 54.7 (45.7–61.4) | 23.5 (22.4–26.3) |
| iDose4 | 4 [4–4]* | 0 [0] | 1 [5] | 32.2 (29.0–37.1)* | 32.4 (28.5–36.1)* | 37.4 (30.8–42.0)* | 35.6 (29.6–37.3)* | 17.7 (16.9–17.7)* |
| MIR (BR) | 4 [4–4]* | 0 [0] | 0 [0] | 10.2 (9.5–11.6)* | 11.5 (10.0–12.3)* | 11.7 (10.0–13.6)* | 13.0 (11.4–14.8)* | 6.6 (5.7–7.3)* |
| MIR (ST) | 4 [4–4]* | 0 [0] | 0 [0] | 7.2 (6.2–8.2)* | 7.5 (7.0–8.0)* | 7.7 (6.0–9.5)* | 9.1 (7.6–10.9)* | 4.2 (4.0–7.3)* |
| 40% reduced dose | ||||||||
| FBP | 3 [3–3] | 3 [16] | 15 [79] | 70.0 (62.8–83.5)* | 72.2 (63.5–79.3)* | 77.3 (69.6–97.0)* | 74.8 (55.6–83.8)* | 31.7 (25.9–37.7)* |
| iDose4 | 3 [3–4] | 0 [0] | 8 [42] | 37.8 (34.6–39.7)* | 38.0 (34.2–42.4)* | 44.0 (37.7–45.7)* | 39.4 (36.2–44.2)* | 23.6 (20.0–28.6) |
| MIR (BR) | 4 [3–4]* | 0 [0] | 4 [21] | 12.4 (10.2–12.8)* | 11.6 (9.8–14.4)* | 13.6 (11.4–15.7)* | 13.5 (11.2–17.6)* | 7.5 (5.9–8.6)* |
| MIR (ST) | 4 [3–4]* | 0 [0] | 2 [11] | 8.4 (7.3–9.8)* | 9.3 (7.3–10.7)* | 10.2 (9.4–11.3)* | 10.5 (8.9–14.3)* | 5.6 (4.9–7.9)* |
| 60% reduced dose | ||||||||
| FBP | 2 [2–3]* | 13 [68] | 19 [100] | 97.5 (84.1–106.7)* | 88.7 (77.4–120.8)* | 103.1 (89.8–115.0)* | 103.7 (85.6–111.1)* | 42.2 (33.0–49.8)* |
| iDose4 | 3 [3–3] | 0 [0] | 6 [32] | 40.6 (38.9–45.1)* | 39.3 (35.8–48.1)* | 46.2 (40.2–52.5)* | 45.6 (38.3–49.5)* | 27.4 (24.5–37.2)* |
| MIR (BR) | 4 [3–4] | 1 [5] | 7 [37] | 13.7 (11.2–15.6)* | 12.9 (10.8–14.6)* | 15.2 (13.1–17.4)* | 14.2 (12.5–16.4)* | 8.5 (7.3–11.7)* |
| MIR level 2 (ST) | 3 [3–4]* | 0 [0] | 2 [5] | 10.1 (8.3–12.0)* | 9.2 (8.6–10.7)* | 11.6 (10.1–13.3)* | 10.2 (9.2–12.3)* | 7.2 (5.3–10.5)* |
| 80% reduced dose | ||||||||
| FBP | 1 [1–1]* | 19 [100] | 19 [100] | 160.9 (136.0–187.6)* | 168.7 (131.0–192.9)* | 184.7 (152.8–203.3)* | 165.6 (146.9–187.5)* | 57.2 (36.8–63.2)* |
| iDose4 | 2 [2–3]* | 11 [58] | 17 [90] | 47.4 (45.3–64.7) | 51.0 (45.4–59.0) | 50.6 (44.3–63.6) | 51.8 (48.0–64.7) | 33.4 (26.8–41.7)* |
| MIR (BR) | 3 [3–3]* | 4 [21] | 14 [74] | 15.9 (12.9–17.2)* | 14.6 (12.3–17.8)* | 17.1 (15.6–19.4)* | 15.2 (13.9–19.1)* | 9.8 (8.8–15.4)* |
| MIR (ST) | 3 [2–3]* | 6 [32] | 13 [69] | 12.4 (9.9–13.9)* | 11.8 (10.3–14.7)* | 14.4 (11.8–16.0)* | 12.5 (10.5–15.7)* | 9.2 (6.4–15.1)* |
*Significant difference compared to the reference (p<0.0125)
FBP filtered back projection, HIR hybrid iterative reconstruction, MIR model-based iterative reconstruction, BR body routine, ST soft tissue, Obs observer